Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

Nikolas Herold,Sean G. Rudd,Linda Ljungblad,Kumar Sanjiv,Ida Hed Myrberg,Cynthia B.J. Paulin,Yaser Heshmati,Anna Hagenkort,Juliane Kutzner,Brent D. G. Page,José Manuel Calderón-Montaño,Olga Loseva,Ann-Sofie Jemth,Lorenzo Bulli,Hanna Axelsson,Bianca Tesi,Nicholas C.K. Valerie,Andreas Höglund,Julia Bladh,Elisee Wiita,Mikael Sundin,Michael Uhlin,Georgios Rassidakis,Mats Heyman,Katja Pokrovskaja Tamm,Ulrika Warpman Berglund,Julian Walfridsson,Sören Lehmann,Dan Grandér,Thomas Lundbäck,Per Kogner,Jan-Inge Henter,Thomas Helleday,Torsten Schaller

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

2017

The therapeutic response of acute myelogenous leukemia to the nucleoside analog ara-C is controlled by SAMHD1, an enzyme that hydrolyzes the activemetabolite ara-CTP.

Keywords:

Virology
Immunology
SAMHD1
Enzyme
Myelogenous
Nucleoside
Hematology
Cytarabine
Medicine
Leukemia
Internal medicine
Ectopic expression
Myeloid
DNA damage

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations